Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cocrystal Pharma Inc

Current price
2.25 USD 0 USD (0.00%)
Last closed 2.2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 22 382 360 USD
Yield for 12 month +0.90 %
21.11.2021 - 28.11.2021

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington. Address: 19805 North Creek Parkway, Bothell, WA, United States, 98011

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

8.67 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+144 000 USD

Current Year

+1 388 000 USD

Last Year

-241 600 USD

Current Quarter

-35 000 USD

Last Quarter

+72 000 USD

Key Figures COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -20 031 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -39.23 %
PEG Ratio
Return On Equity TTM -58.52 %
Wall Street Target Price 8.67 USD
Revenue TTM 510 000 USD
Book Value 2.22 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 26.9 %
Dividend Yield
Gross Profit TTM -8 794 000 USD
Earnings per share -1.62 USD
Diluted Eps TTM -1.62 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics COCP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:12
Payout Ratio
Last Split Date 11.10.2022
Dividend Date 24.01.2018

Stock Valuation COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 17.8912
Price Sales TTM 92.4548
Enterprise Value EBITDA 0.4607
Price Book MRQ 0.5591

Financials COCP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators COCP

For 52 weeks

1.33 USD 3.29 USD
50 Day MA 1.62 USD
Shares Short Prior Month 7 990
200 Day MA 1.81 USD
Short Ratio 0.32
Shares Short 6 280
Short Percent 0.08 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics